Cargando…

The EPH/Ephrin System in Pancreatic Ductal Adenocarcinoma (PDAC): From Pathogenesis to Treatment

Pancreatic ductal adenocarcinoma (PDAC) is a major concern for health care systems worldwide, since its mortality remains unaltered despite the surge in cutting-edge science. The EPH/ephrin signaling system was first investigated in the 1980s. EPH/ephrins have been shown to exert bidirectional signa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Papadakos, Stavros P., Dedes, Nikolaos, Gkolemi, Nikolina, Machairas, Nikolaos, Theocharis, Stamatios
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917762/ https://www.ncbi.nlm.nih.gov/pubmed/36769332 http://dx.doi.org/10.3390/ijms24033015

Ejemplares similares

Unraveling the Significance of EPH/Ephrin Signaling in Liver Cancer: Insights into Tumor Progression and Therapeutic Implications
por: Papadakos, Stavros P., et al.
Publicado: (2023)

Exosomes in the Treatment of Pancreatic Cancer: A Moonshot to PDAC Treatment?
por: Papadakos, Stavros P., et al.
Publicado: (2022)

The EPH/Ephrin System in Colorectal Cancer
por: Papadakos, Stavros P., et al.
Publicado: (2022)

Utilizing Exosomal-EPHs/Ephrins as Biomarkers and as a Potential Platform for Targeted Delivery of Therapeutic Exosomes
por: Goutas, Dimitrios, et al.
Publicado: (2022)

EPH/Ephrin Signaling in Normal Hematopoiesis and Hematologic Malignancies: Deciphering Their Intricate Role and Unraveling Possible New Therapeutic Targets
por: Stergiou, Ioanna E., et al.
Publicado: (2023)

The Clinical Impact of the EPH/Ephrin System in Cancer: Unwinding the Thread
por: Pergaris, Alexandros, et al.
Publicado: (2021)

The Role of the NLRP3 Inflammasome in HCC Carcinogenesis and Treatment: Harnessing Innate Immunity
por: Papadakos, Stavros P., et al.
Publicado: (2022)

The EPH/Ephrin System in Bone and Soft Tissue Sarcomas’ Pathogenesis and Therapy: New Advancements and a Literature Review
por: Hadjimichael, Argyris C., et al.
Publicado: (2022)

Overexpression of Mesothelin in Pancreatic Ductal Adenocarcinoma (PDAC)
por: Le, Kai, et al.
Publicado: (2020)

The EPH/Ephrin System in Gynecological Cancers: Focusing on the Roots of Carcinogenesis for Better Patient Management
por: Psilopatis, Iason, et al.
Publicado: (2022)

Ephrin Receptors (Ephs) Expression in Thymic Epithelial Tumors: Prognostic Implications and Future Therapeutic Approaches
por: Masaoutis, Christos, et al.
Publicado: (2021)

Modifiable Pancreatic Ductal Adenocarcinoma (PDAC) Risk Factors
por: Michalak, Natalia, et al.
Publicado: (2023)

May EPH/Ephrin Targeting Revolutionize Lung Cancer Treatment?
por: Psilopatis, Iason, et al.
Publicado: (2022)

Systemic therapy in pancreatic ductal adenocarcinomas (PDACs)—basis and current status
por: Ramaswamy, Anant, et al.
Publicado: (2022)

Ephrin Receptors (Eph): EphA1, EphA5, and EphA7 Expression in Uveal Melanoma—Associations with Clinical Parameters and Patient Survival
por: Gajdzis, Malgorzata, et al.
Publicado: (2020)

Clinically impactful metabolic subtypes of pancreatic ductal adenocarcinoma (PDAC)
por: Pervin, Jannat, et al.
Publicado: (2023)

The role of survivin in the progression of pancreatic ductal adenocarcinoma (PDAC) and a novel survivin-targeted therapeutic for PDAC
por: Brown, Matthew, et al.
Publicado: (2020)

EPH/Ephrin-Targeting Treatment in Breast Cancer: A New Chapter in Breast Cancer Therapy
por: Psilopatis, Iason, et al.
Publicado: (2022)

ANO1 (TMEM16A) in pancreatic ductal adenocarcinoma (PDAC)
por: Sauter, D. R. P., et al.
Publicado: (2014)

The microbiome as a potential diagnostic biomarker for pancreatic ductal adenocarcinoma (PDAC)
por: Wheatley, Roseanna C., et al.
Publicado: (2022)

Regulatory role of RNA modifications in the treatment of pancreatic ductal adenocarcinoma (PDAC)
por: Chen, Hao, et al.
Publicado: (2023)

SIRT 1 Overexpression is Associated with Metastasis of Pancreatic Ductal Adenocarcinoma (PDAC) and Promotes Migration and Growth of PDAC Cells
por: Li, Siqin, et al.
Publicado: (2016)

Ephrin (Eph) receptor A1, A4, A5 and A7 expression in human non-small cell lung carcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients’ survival
por: Giaginis, Constantinos, et al.
Publicado: (2014)

MicroRNAs as Indicators of Malignancy in Pancreatic Ductal Adenocarcinoma (PDAC) and Cystic Pancreatic Lesions
por: Prinz, Christian, et al.
Publicado: (2022)

Unveiling the Yin-Yang Balance of M1 and M2 Macrophages in Hepatocellular Carcinoma: Role of Exosomes in Tumor Microenvironment and Immune Modulation
por: Papadakos, Stavros P., et al.
Publicado: (2023)

Simple Serum Pancreatic Ductal Adenocarcinoma (PDAC) Protein Biomarkers—Is There Anything in Sight?
por: Kapszewicz, Monika, et al.
Publicado: (2021)

Eph-ephrin signaling in nervous system development
por: Cramer, Karina S., et al.
Publicado: (2016)

Perineural Invasion in Pancreatic Ductal Adenocarcinoma (PDAC): A Saboteur of Curative Intended Therapies?
por: Felsenstein, Matthäus, et al.
Publicado: (2022)

Screening of potential pain genes in pancreatic ductal adenocarcinoma (PDAC) based on bioinformatics methods
por: Xu, Qian, et al.
Publicado: (2023)

Eph-A2 and Eph-A4 expression in human benign and malignant thyroid lesions: An immunohistochemical study
por: Karidis, Nikolaos P., et al.
Publicado: (2011)

The Emerging Role of Metformin in the Treatment of Hepatocellular Carcinoma: Is There Any Value in Repurposing Metformin for HCC Immunotherapy?
por: Papadakos, Stavros P., et al.
Publicado: (2023)

The Role of Ephs and Ephrins in Memory Formation
por: Dines, Monica, et al.
Publicado: (2015)

Ephs and Ephrins in Adult Endothelial Biology
por: Vreeken, Dianne, et al.
Publicado: (2020)

Eph Receptors and Ephrins in Retinal Diseases
por: Kaczmarek, Radoslaw, et al.
Publicado: (2021)

Eph and ephrin signaling in the development of the central auditory system
por: Krasewicz, Jakub, et al.
Publicado: (2022)

Upregulated MicroRNA-483-3p is an Early Event in Pancreatic Ductal Adenocarcinoma (PDAC) and as a Powerful Liquid Biopsy Biomarker in PDAC
por: Shao, Huilin, et al.
Publicado: (2021)

Neurotensin is a Versatile Modulator of In Vitro Human Pancreatic Ductal Adenocarcinoma Cell (PDAC) Migration
por: Mijatovic, Tatjana, et al.
Publicado: (2007)

Neutrophil–lymphocyte ratio (NLR) was associated with prognosis and immunomodulatory in patients with pancreatic ductal adenocarcinoma (PDAC)
por: Xiang, Zi-jun, et al.
Publicado: (2020)

PDAC-ANN: an artificial neural network to predict pancreatic ductal adenocarcinoma based on gene expression
por: Almeida, Palloma Porto, et al.
Publicado: (2020)

Circulating Tumor Cell Subpopulations Predict Treatment Outcome in Pancreatic Ductal Adenocarcinoma (PDAC) Patients
por: Freed, Ian M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fh06r403b89jbsloa2st9qroat